A life sciences-focused venture capital firm with offices in Europe focuses on disruptive early-stage life sciences companies and invests primarily in therapeutics. The firm is actively investing through its latest fund and has built a portfolio of multiple startups through both direct investments and company creation initiatives. The firm invests predominantly in Europe, with a strong emphasis on opportunities in Western Europe.
The firm invests primarily in therapeutics and does not currently focus on medical devices, diagnostics, or digital health. The firm is modality-agnostic and evaluates a broad range of therapeutic approaches. Areas of strongest interest include oncology, immuno-oncology, rare and orphan diseases, infectious diseases, and immunology. The firm typically invests from preclinical through early clinical stages and focuses on opportunities with the potential to become first- or best-in-class therapies.
From a company and management team perspective, the firm is open to working with both experienced operators and first-time entrepreneurs and has supported several companies led by first-time CEOs. The firm places strong emphasis on diversity in leadership and maintains a hands-on investment approach, actively mentoring and supporting portfolio companies. The firm is open to acting as either a lead investor or co-investor and works closely with scientific founders, academic institutions, and syndicate partners to help companies scale and mature.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment